Phase II Study of Atorvastatin, Micro-dose Methotrexate and Tacrolimus Administered Only to Transplant Recipients for the Prophylaxis of Acute Graft-versus-host Disease Following Allogeneic Hematopoietic Cell Transplantation
Latest Information Update: 17 May 2023
At a glance
- Drugs Atorvastatin (Primary) ; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 09 Sep 2021 Status changed from active, no longer recruiting to completed.
- 14 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2023.
- 14 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2023.